{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:45Z","timestamp":1792800885679,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nephrotic syndrome is characterized by significant proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Patients frequently exhibit hypercoagulability on account of endothelial dysfunction and abnormal blood coagulation function, which significantly heighten the risk of thrombus formation. Although anticoagulant therapy is crucial for preventing thrombotic events, formulating individualized anticoagulation treatment plans for these patients remains a challenge in clinical practice due to variations in renal function and the distinct metabolic characteristics of anticoagulant medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Introduction<\/jats:title><jats:p>This case report presents a 27-year-old male patient diagnosed with nephrotic syndrome. The etiological diagnosis was hepatitis B virus-associated glomerulonephritis, and the pathological diagnosis was mesangial proliferative glomerulonephritis. The patient had a relapse accompanied by bilateral pulmonary embolism and a right ventricular thrombus, and ultimately underwent thrombectomy. In the subsequent year, despite receiving adequate anticoagulation therapy with rivaroxaban, rare events of descending aortic mural thrombus and bilateral renal infarction occurred. The patient was treated with anticoagulation, endovascular exclusion with a descending aorta covered stent for the isolation of mural thrombus, and prolonged antiplatelet therapy. As of now, follow-up has shown no recurrence of thrombotic events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case underscores the challenges associated with managing the hypercoagulability in patients with nephrotic syndrome and emphasizes the importance of personalized anticoagulation therapy. To improve patient outcomes, future research should focus on the selection of anticoagulant agents, dosage optimization, and monitoring strategies to enhance the safety and efficacy of anticoagulation treatment in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1514801","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:49:53Z","timestamp":1738133393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From the right ventricle to the descending aorta: a Case Report of complex thrombotic events in a patient with nephrotic syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaojiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s005950200199","article-title":"Left atrial thrombus without mitral valve disease in a patient with nephrotic syndrome: report of a case","volume":"32","author":"Aoyagi","year":"2002","journal-title":"Surg. Today"},{"key":"B2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1055\/s-0033-1343887","article-title":"Thrombosis in nephrotic syndrome","volume":"39","author":"Barbano","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B4","first-page":"454","article-title":"Right atrial thrombus mimicking myxoma with pulmonary embolism in a patient with systemic lupus erythematosus and secondary antiphospholipid syndrome","volume":"35","author":"Cianciulli","year":"2008","journal-title":"Tex Heart Inst. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0000000000000800","article-title":"Rivaroxaban and the EINSTEIN clinical trial programme","volume":"30","author":"Cohen","year":"2019","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jccase.2016.07.005","article-title":"Intra-cardiac thrombus in antiphospholipid antibody syndrome: an unusual cause of fever of unknown origin with review of literature","volume":"14","author":"Dhibar","year":"2016","journal-title":"J. Cardiol. Cases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11748-013-0314-5","article-title":"Right ventricular thrombus in a patient with nephrotic syndrome","volume":"63","author":"Fukui","year":"2015","journal-title":"Gen. Thorac. Cardiovasc Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.14218\/JCTH.2014.00031","article-title":"Thrombosis associated with viral hepatitis","volume":"2","author":"Galli","year":"2014","journal-title":"J. Clin. Transl. Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.3969\/j.issn.1005-9202.2015.12.133","article-title":"Risk factors, pathologic mechanisms and prevention of thrombosis in patients with nephrotic syndrome","author":"Gao","year":"2015","journal-title":"Chin. J. Gerontology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.16833\/j.cnki.jbmc.2020.01.012","article-title":"The clinical efficacy of rivaroxaban and traditional anticoagulation therapy in elderly patients with pulmonary thromboembolism","volume":"36","author":"Ge","year":"2020","journal-title":"J. Baotou Med. Coll."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1681\/ASN.2006111300","article-title":"Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrume: a clinical conundrum","volume":"18","author":"Glassock","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2215\/CJN.05250419","article-title":"Prophylactic anticoagulation in adult patients with nephrotic syndrome","volume":"15","author":"Gordon-Cappitelli","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/000331970105200610","article-title":"A giant left ventricular thrombus in a patient with acute myocardial infarction--a case report","volume":"52","author":"Hirano","year":"2001","journal-title":"Angiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0167-5273(95)02366-5","article-title":"Biventricular thrombi in diabetic nephrotic syndrome complicated by cerebral embolism","volume":"50","author":"Huang","year":"1995","journal-title":"Int. J. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/BF00311828","article-title":"Left ventricular thrombosis following coronary artery bypass grafting in a patient with nephrotic syndrome: report of a case","volume":"25","author":"Kioka","year":"1995","journal-title":"Surg. Today"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3760\/cma.j.cn431274-20191111-01319","article-title":"Clinical observation on the anticoagulant therapy of rivaroxaban in idiopathic membranous nephropathy","volume":"22","author":"L\u00fc","year":"2020","journal-title":"J. Chin. Physician."},{"key":"B19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3969\/j.issn.1002-1949.2019.06.001","article-title":"Chinese Consensus on antithrombotic therapy for acute thrombotic diseases","volume":"39","author":"Ma","year":"2019","journal-title":"Chin. J. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/ndt\/11.8.1627","article-title":"Intracardiac thrombus in an adult patient with nephrotic syndrome","volume":"11","author":"Mak","year":"1996","journal-title":"Nephrol. Dial. Transpl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000013323","article-title":"Intraventricular and brachial artery thrombosis in nephrotic syndrome","volume":"18","author":"Malik","year":"1998","journal-title":"Am. J. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103447","DOI":"10.1016\/j.autrev.2023.103447","article-title":"Risk of venous thromboembolism in autoimmune diseases: a comprehensive review","volume":"22","author":"Menichelli","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ndt\/gfad225","article-title":"Membranous nephropathy treatment standard","volume":"39","author":"Radhakrishnan","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"key":"B25","first-page":"825","article-title":"Asymptomatic right atrial thrombus in a case of nephrotic syndrome","volume":"19","author":"Raj","year":"2006","journal-title":"J. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40620-018-0552-9","article-title":"Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy","volume":"32","author":"Reynolds","year":"2019","journal-title":"J. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s11255-023-03474-8","article-title":"Research progress of nephrotic syndrome accompanied by thromboembolism","volume":"55","author":"Tian","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1055\/a-1920-6224","article-title":"Apixaban prophylactic anticoagulation in patients with nephrotic syndrome","volume":"6","author":"Van Meerhaeghe","year":"2022","journal-title":"TH Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.thromres.2021.02.007","article-title":"Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy","volume":"201","author":"Waller","year":"2021","journal-title":"Thromb. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2023.0354","article-title":"Thromboembolic phenomena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment","volume":"85","author":"Wang","year":"2024","journal-title":"Br. J. Hosp. Med. (Lond)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3760\/cma.j.issn.2095-428X.2016.05.004","article-title":"Diagnosis and management of complications in nephrotic syndrome","volume":"31","author":"Zhao","year":"2016","journal-title":"Chin. J. Appl. Clin. Pediatr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1514801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:49:59Z","timestamp":1738133399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1514801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1514801"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1514801","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"1514801"}}